Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525707 · ClinicalTrials.gov registry record · Phase 3
Tezosentan in Acute Heart Failure
A Phase 3 study of Acute Heart Failure and Acute Decompensation of Chronic Heart Failure, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 735
- Enrollment target
- 20
- Study locations
NCT00525707: Completed Phase 3 study of Acute Heart Failure and Acute Decompensation of Chronic Heart Failure, sponsored by Idorsia Pharmaceuticals.
NCT00525707 is a Phase 3 study of Acute Heart Failure and Acute Decompensation of Chronic Heart Failure that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 735 participants, below the 1,361-participant average among 8 other Acute Heart Failure trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525707, a Phase 3 study of Acute Heart Failure and Acute Decompensation of Chronic Heart Failure, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 735 participants
- Enrollment target
- 20
- Study locations
Study Summary
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up period of 5 months for vital status.
Conditions Studied
Interventions
- DRUG tezosentan
Study Locations (20)
Other
- AKH University of Vienna, Abt. Medizinische Kardiologie - Vienna
- Roskilde Amt Sygehus - Roskilde
- Hopital Ambroise Pare, Service de Cardiologie - Boulogne
- Heart Failure clinic C.H. Dubos - Pontoise
- Hopitaux Universitaires de Strasbourg, Hopital Hautepierre - Strasbourg
- CHU Rangueil, Cardiologie A - Toulouse
- Medizinische Klinik I, Universitatsklinikum Aachen - Aachen
- Campus Virchow-Klinikum, Medizinishe Klinik mit Schwerpunkt Kardiologie - Berlin
- Georg-August-Universitat Gottingen, Zentrum fur Innere Med - Göttingen
- Dept. of Cardiology, University of Athens, Alexandra Hospital - Athens
- Barzilai Hospital - Ashkelon
- Carmel Medical Center - Haifa
Texas
- Veterans Affairs Medical Center - Houston
- Tyler Cardiovascular Consultants - Tyler
Alabama
- University of Alabama-Birmingham - Birmingham
California
- Advanced Heart Failure and Transplant Service, Palo Alto VA Health Care System, Cardiology Section - Palo Alto
Colorado
- Denver VAMC - Denver
Pennsylvania
- The Heart Hospital at Alledgheny General, Division of Cardiology - Pittsburgh
Virginia
- Danville Medical Center - Danville
Washington
- Medical Associates, Bellebue - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
What the finished NCT00525707 record still lists
NCT00525707 is an interventional study that assigns participants to a tested intervention. The registered 735 participants enrollment target is mid-sized for trials with a published cap, below the 1,361-participant average among 8 other Acute Heart Failure trials with a reported enrollment target (46% lower).
The record links to 3 conditions, with Acute Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which tezosentan is the first listed.
NCT00525707 names 20 study sites across 8 states, led by Other, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00525707 about?
NCT00525707 is a clinical study titled "Tezosentan in Acute Heart Failure". The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours ...
What is the current status of trial NCT00525707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 735 participants. The study started on 2003-04. Estimated completion is 2005-01.
What conditions does trial NCT00525707 study?
This clinical trial studies the following conditions: Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure.
What interventions are being tested in trial NCT00525707?
The interventions under investigation include: tezosentan (DRUG).
Who is sponsoring clinical trial NCT00525707?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00525707 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00525707's enrollment target sits among peer trials
735 5th of 8 higher than 4 of 8 other Acute Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
-
Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.
COMPLETED · Phase 3
-
Improving Diagnostic Accuracy for Acute Heart Failure
ACTIVE NOT RECRUITING
-
Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)
ACTIVE NOT RECRUITING · Phase 2
-
Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot
COMPLETED · Phase 1
-
An Observational Study of the Functional Capacity of Heart Failure
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- NCT06825689 · 735 participants · NA
Unidos Contra el VPH
- NCT05796141 · 736 participants · NA
Becoming United in Lifestyle Decisions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia